Trial Profile
A retrospective study evaluating safety of ipilimumab and nivolumab in patients with advanced melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 26 May 2018 New trial record
- 23 May 2018 Results presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research